NASDAQ$ANNX
Annexon Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Annexon reported fourth quarter and year-end 2022 financial results and reiterated anticipated milestones.
Annexon reported a net loss of $34.4 million for the quarter ended December 31, 2022, and cash and cash equivalents and short-term investments were $242.7 million as of December 31, 2022.
- Initiated dosing in Phase 1 Multiple-Ascending Dose (MAD) Trial of ANX1502.
- Completed expanded enrollment in the ongoing pivotal Phase 3 trial of ANX005 in patients with Guillain-Barré syndrome (GBS) in 2023 with pivotal data anticipated in the first half of 2024.
- Completed the ongoing SAD trial of ANX1502 and identify the maximum tolerated dose; execute the ongoing MAD trial in healthy volunteers; and initiate a proof-of-concept study in patients with cold agglutinin disease (CAD) in 2023.
- Completed the ongoing Phase 2 trial of ANX007 in patients with geographic atrophy (GA) and report initial data in mid-2023 followed by additional data by the end of 2023 after the conclusion of the six-month off-treatment period.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$0
Forward guidance
Annexon expects its cash, cash equivalents and marketable securities as of December 31, 2022, to be sufficient to fund the company’s current operating plan into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro